Dr. D.H. van Raalte MD publications

foto

Publications Dr. D.H. van Raalte MD

Main activities
Patient care, Research, Teaching

2018

  • Deschasaux M, Bouter KE, Prodan A, Levin E , Groen AK, Herrema H, Tremaroli V, Bakker GJ, Attaye I, Pinto-Sietsma SJ, van Raalte DH, Snijder MB, Nicolaou M, Peters R, Zwinderman AH, Bäckhed F, Nieuwdorp M, Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. NAT MED 2018;24 (10):1526-+ [PubMed]
  • Emanuel AL, de Clercq NC, Koopen AM, van Poelgeest E, Serlie MJM, van Raalte DH, Kramer MHH, Nieuwdorp M, Eringa EC, Serné EH, Iloprost infusion prevents the insulin-induced reduction in skeletal muscle microvascular blood volume but does not enhance peripheral glucose uptake in type 2 diabetic patients. DIABETES OBES METAB 2018;20 (11):2523-2531 [PubMed]
  • Pranger IG, van Raalte DH, Brands M, Muskiet MHA, Kema IP, Serlie MJ, Diamant M, Bakker SJL, Muskiet FAJ, Influence of prednisolone on parameters of de novo lipogenesis and indices for stearoyl-CoA- and Delta 6-desaturase activity in healthy males: A Post-hoc analysis of a randomized, placebo-controlled, double-blind trial. PROSTAG LEUKOTR ESS 2018;132:8-15 [PubMed]
  • van Bommel EJM, de Jongh RT, Brands M, Heijboer AC, den Heijer M, Serlie MJ, van Raalte DH, The osteoblast: Linking glucocorticoid-induced osteoporosis and hyperglycaemia? A post-hoc analysis of a randomised clinical trial. BONE 2018;112:173-176 [PubMed]

2017

  • Bouter KE, van Raalte DH, Groen AK, Nieuwdorp M, Role of the Gut Microbiome in the Pathogenesis of Obesity and Obesity-Related Metabolic Dysfunction. GASTROENTEROLOGY 2017;152 (7):1671-1678 [PubMed]
  • Brouwer A, Nguyen HT, Snoek FJ, van Raalte DH, Beekman ATF, Moll AC, Bremmer MA, Light therapy: is it safe for the eyes?. ACTA PSYCHIAT SCAND 2017;136 (6):534-548 [PubMed]
  • De Groot PF , Belzer C, Aydin Ö, Levin E , Levels JH, Aalvink S, Boot F, Holleman F, van Raalte DH, Scheithauer TP, Simsek S, Schaap FG, Olde Damink SWM, Roep BO, Hoekstra JB, de Vos WM, Nieuwdorp M, Distinct fecal and oral microbiota composition in human type 1 diabetes, an observational study. PLOS ONE 2017;12 (12):e0188475 [PubMed]
  • Emanuel AL, Meijer RI, Muskiet MHA, van Raalte DH, Eringa EC, Serne EH, Role of Insulin-Stimulated Adipose Tissue Perfusion in the Development of Whole-Body Insulin Resistance. ARTERIOSCL THROM VAS 2017;37 (3):411-418 [PubMed]
  • Muskiet MHA, Heerspink HJL, van Raalte DH, SGLT2 inhibition: a new era in renoprotective medicine?. LANCET DIABETES ENDO 2017;5 (8):569-571 [PubMed]
  • Muskiet MHA, Tonneijck L, Smits MM, van Baar MJB, Kramer MHH, Hoorn EJ, Joles JA, van Raalte DH, GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. NAT REV NEPHROL 2017;13 (10):605-628 [PubMed]
  • Smits MM. Gastrointestinal and Cardiovascular Effects of Incretin-Based Therapies: Friend or Foe?. S.l.: s.n.; 2017. 258p. ISBN 978-94-6182-833-0 Proefschrift VU University, Amsterdam, -. (Promotor(s): Kramer MHH; copromotor(s): van Raalte DH, Cahen DL)
  • Smits MM, Tonneijck L, Muskiet MHA, Diamant M, Kramer MHH, Cahen DL, van Raalte DH, Acute plasma amylase increase after glucagon-like peptide-1 receptor agonist exenatide administration in Type 2 diabetes. DIABETIC MED 2017;34 (4):591-592 [PubMed]
  • Smits MM, Tonneijck L, Muskiet MHA, Hoekstra T, Kramer MHH, Diamant M, van Raalte DH, Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial. EUR J ENDOCRINOL 2017;176 (1):77-86 [PubMed]
  • Smits MM, Tonneijck L, Muskiet MHA, Hoekstra T, Kramer MHH, Diamant M, van Raalte DH, The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients. DIABETES RES CLIN PR 2017;124:1-10 [PubMed]
  • Smits MM, Tonneijck L, Muskiet MHA, Kramer MHH, Pieters-van den Bos IC, Vendrik KEW, Hoekstra T, Bruno MJ, Diamant M, van Raalte DH, Cahen DL, Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial. DIABETES CARE 2017;40 (3):301-308 [PubMed]
  • Tonneijck L, Muskiet MHA, Smits MM, Hoekstra T, Kramer MHH, Danser AHJ, Diamant M, Joles JA, van Raalte DH, Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial. DIABETES OBES METAB 2017;19 (12):1669-1680 [PubMed]
  • Tonneijck L, Muskiet MHA, Smits MM, van Bommel EJ, Heerspink HJL, van Raalte DH, Joles JA, Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. J AM SOC NEPHROL 2017;28 (4):1023-1039 [PubMed]
  • Tonneijck L, van Raalte DH, Muskiet MHA, Liraglutide and Renal Outcomes in Type 2 Diabetes. NEW ENGL J MED 2017;377 (22):2195 [PubMed]
  • Udayappan SD, Kovatcheva-Datchary P, Bakker GJ, Havik SR, Herrema H, Cani PD, Bouter KE, Belzer C, Witjes JJ, Vrieze A , de Sonnaville N, Chaplin A, van Raalte DH, Aalvink S, Dallinga-Thie GM, Heilig HGHJ, Bergström G, van der Meij S, van Wagensveld BA, Hoekstra JBL, Holleman F, Stroes ESG, Groen AK, Bäckhed F, de Vos WM, Nieuwdorp M, Intestinal Ralstonia pickettii augments glucose intolerance in obesity. PLOS ONE 2017;12 (11):e0181693 [PubMed]
  • van Baar MJB, van Raalte DH, Muskiet MHA, 1-67in Patients With Type 2 Diabetes. Diabetes Care 2017;40:1073-1081. DIABETES CARE 2017;40 (11):e157-e158 [PubMed]
  • van Bommel EJM, Muskiet MHA, Tonneijck L, Kramer MHH, Nieuwdorp M, van Raalte DH, SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. CLIN J AM SOC NEPHRO 2017;12 (4):700-710 [PubMed]
  • van Raalte DH, Verchere CB, Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?. DIABETES OBES METAB 2017;19 (9):1205-1213 [PubMed]
  • Vendrik KEW, Tonneijck L, Muskiet MHA, Kramer MHH, Pouwels PJW, Pieters-van den Bos IC, Diamant M, Cahen DL, van Raalte DH, Smits MM, Pancreatic Steatosis Is Not Associated With Exocrine Pancreatic Function in Overweight Type 2 Diabetes Patients. PANCREAS 2017;46 (9):e75-e76 [PubMed]

2016

  • Muskiet MHA, Tonneijck L, Smits MM, Kramer MHH, Diamant M, Joles JA, van Raalte DH, Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men. DIABETES OBES METAB 2016;18 (2):178-185 [PubMed]
  • Muskiet MHA, Tonneijck L, van Bommel EJM, Smits MM, van Raalte DH, Renoprotection in LEADER and EMPA-REG OUTCOME. LANCET DIABETES ENDO 2016;4 (10):812-814 [PubMed]
  • Muskiet MHA, van Bommel EJM, van Raalte DH, Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes. LANCET DIABETES ENDO 2016;4 (3):188-189 [PubMed]
  • Scheithauer TPM, Dallinga-Thie GM, de Vos WM, Nieuwdorp M, van Raalte DH, Causality of small and large intestinal microbiota in weight regulation and insulin resistance. MOL METAB 2016;5 (9):759-770 [PubMed]
  • Smits MM, Bunck MC, Diamant M, Corner A, Eliasson B, Heine RJ, Smith U, Yki-Järvinen H, van Raalte DH, Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels. DIABETES CARE 2016;39 (3):e42-e43 [PubMed]
  • Smits MM, Muskiet MHA, Tonneijck L, Hoekstra T, Kramer MHH, Diamant M, van Raalte DH, Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males. BRIT J CLIN PHARMACO 2016;81 (4):613-620 [PubMed]
  • Smits MM, Tonneijck L, Muskiet MHA, Hoekstra T, Kramer MHH, Diamant M, Nieuwdorp M, Groen AK, Cahen DL, van Raalte DH, Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. DIABETES OBES METAB 2016;18 (12):1217-1225 [PubMed]
  • Smits MM, Tonneijck L, Muskiet MHA, Hoekstra T, Kramer MHH, Diamant M, Serné EH, van Raalte DH, GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial. ARTERIOSCL THROM VAS 2016;36 (10):2125-2132 [PubMed]
  • Smits MM, Tonneijck L, Muskiet MHA, Kramer MHH, Cahen DL, van Raalte DH, Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. DIABETES OBES METAB 2016;18 (3):224-235 [PubMed]
  • Smits MM, Tonneijck L, Muskiet MHA, Kramer MHH, Diamant M, Pieters-van den Bos IC, van Raalte DH, Cahen DL, Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial. DIABETES OBES METAB 2016;18 (3):281-288 [PubMed]
  • Smits MM, Tonneijck L, Muskiet MHA, Kramer MHH, Pouwels PJW, Pieters-van den Bos IC, Hoekstra T, Diamant M, van Raalte DH, Cahen DL, Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. DIABETOLOGIA 2016;59 (12):2588-2593 [PubMed]
  • Smits MM, van Raalte DH, Tonneijck L, Muskiet MHA, Kramer MHH, Cahen DL, GLP-1 based therapies: clinical implications for gastroenterologists. GUT 2016;65 (4):702-711 [PubMed]
  • Tonneijck L, Smits MM, Muskiet MHA, Hoekstra T, Kramer MHH, Danser AHJ, Diamant M, Joles JA, van Raalte DH, Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. DIABETOLOGIA 2016;59 (7):1412-1421 [PubMed]
  • Tonneijck L, Smits MM, Muskiet MHA, Hoekstra T, Kramer MHH, Danser AHJ, ter Wee PM, Diamant M, Joles JA, van Raalte DH, Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. DIABETES CARE 2016;39 (11):2042-2050 [PubMed]
  • van Raalte DH, Bunck MC, Smits MM, Hoekstra T, Cornér A, Diamant M, Eliasson B, Taskinen MR, Heine RJ, Smith U, Yki-Järvinen H, Mari A, Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial. EUR J ENDOCRINOL 2016;175 (4):345-352 [PubMed]
  • van Raalte DH, Verchere CB, Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?. TRENDS ENDOCRIN MET 2016;27 (7):442-445 [PubMed]

2015

  • Brouwer A, van Raalte DH, Diamant M, Rutters F, van Someren EJW, Snoek FJ, Beekman ATF, Bremmer MA, Light therapy for better mood and insulin sensitivity in patients with major depression and type 2 diabetes: a randomised, double-blind, parallel-arm trial. BMC PSYCHIATRY 2015;15:169 [PubMed]
  • Muskiet MHA, Tonneijck L, Smits MM, Kramer MHH, Heerspink HJL, van Raalte DH, Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. LANCET DIABETES ENDO 2015;3 (5):367-381 [PubMed]
  • Muskiet MHA, Tonneijck L, van Raalte DH, Letter by Muskiet et al Regarding Article, "Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". CIRCULATION 2015;132 (6):e120 [PubMed]
  • Muskiet MHA, van Raalte DH, van Bommel EJM, Smits MM, Tonneijck L, Understanding EMPA-REG OUTCOME. LANCET DIABETES ENDO 2015;3 (12):928-929 [PubMed]
  • Smits MM, Muskiet MHA, Tonneijck L, Kramer MHH, Diamant M, van Raalte DH, Serné EH, GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men. ARTERIOSCL THROM VAS 2015;35 (6):1538-1543 [PubMed]
  • Smits MM, Muskiet MHA, Tonneijck L, van Raalte DH, Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098. DIABETES CARE 2015;38 (7):e106-e107 [PubMed]
  • Smits MM, Tonneijck L, Muskiet MHA, Hoekstra T, Kramer MHH, Pieters IC, Cahen DL, Diamant M, van Raalte DH, Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. BMJ OPEN 2015;5 (11):e009579 [PubMed]
  • Tonneijck L, Smits MM, van Raalte DH, Muskiet MHA, Incretin-based drugs and renoprotection-is hyperfiltration key?. KIDNEY INT 2015;87 (3):660-661 [PubMed]
  • van der Pouw Kraan TCTM, Chen WJ, Bunck MCM, van Raalte DH, van der Zijl NJ, van Genugten RE, van Bloemendaal L, Baggen JM, Serné EH, Diamant M, Horrevoets AJG, Metabolic changes in type 2 diabetes are reflected in peripheral blood cells, revealing aberrant cytotoxicity, a viral signature, and hypoxia inducible factor activity. BMC MED GENOMICS 2015;8:20 [PubMed]
  • van Raalte DH, Beishuizen C, Stradmeijer MD, Houtenbos I, ten Kate RW, Malignant cutaneous lesions. BMJ CASE REP 2015;2015:bcr2015210169 [PubMed]
  • van Raalte DH, Goorden SM, Kemper EA, Brosens LAA, ten Kate RW, Sarcoidosis-related hypercalcaemia due to production of parathyroid hormone-related peptide. BMJ CASE REP 2015;2015:bcr2015210189 [PubMed]
  • van Raalte DH, Vlot MC, Zwijnenburg A, ten Kate RW, F18-Choline PET/CT: a novel tool to localize parathyroid adenoma?. CLIN ENDOCRINOL 2015;82 (6):910-912 [PubMed]
  • Witjes JJ, van Raalte DH, Nieuwdorp M, About the gut microbiome as a pharmacological target in atherosclerosis. EUR J PHARMACOL 2015;763 (Part A):75-78 [PubMed]

2014

  • Heine RJ, Yki-Järvinen H, Kahn SE, van Raalte DH, Michaela Diamant, 11 April 1962-9 April 2014. DIABETOLOGIA 2014;57 (7):1271-1272 [PubMed]
  • Smits MM, Muskiet MHA, Tushuizen ME, Kwa KAA, Karemaker JM, van Raalte DH, Diamant M, Uncomplicated human type 2 diabetes is associated with meal-induced blood pressure lowering and cardiac output increase. DIABETES RES CLIN PR 2014;106 (3):617-626 [PubMed]
  • Tonneijck L, Muskiet MHA, Smits MM, van Raalte DH, Diamant M, Combining incretin-based drugs and RAAS inhibitors: more cons than pros?. LANCET DIABETES ENDO 2014;2 (9):684-685 [PubMed]
  • Tonneijck L, Muskiet MHA, van Raalte DH, ACE-I vs. ARB for blood pressure control in diabetic kidney disease. KIDNEY INT 2014;86 (6):1270 [PubMed]
  • van Genugten RE, van Raalte DH, Muskiet MH, Heymans MW, Pouwels PJW, Ouwens DM, Mari A, Diamant M, Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial. EUR J ENDOCRINOL 2014;170 (3):429-439 [PubMed]
  • van Raalte DH, Diamant M, Steroid diabetes: from mechanism to treatment?. NETH J MED 2014;72 (2):62-72 [PubMed]
  • van Raalte DH, van Genugten RE, Eliasson B, Möller-Goede DL, Mari A, Tura A, Wilson C, Fleck P, Taskinen MR, Smith U, Diamant M, The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes. EUR J ENDOCRINOL 2014;170 (4):565-574 [PubMed]
  • van Raalte DH, Wesselius HM, de Klerk G, Unexpected diagnosis of visceral leishmaniasis in a patient presenting with an infected ICD lead. NETH J MED 2014;72 (3):146-148 [PubMed]

2013

  • Brands M, van Raalte DH, João Ferraz M, Sauerwein HP, Verhoeven AJ, Aerts JMFG, Diamant M, Serlie MJ, No difference in glycosphingolipid metabolism and mitochondrial function in glucocorticoid-induced insulin resistance in healthy men. J CLIN ENDOCR METAB 2013;98 (3):1219-1225 [PubMed]
  • van Genugten RE. Glucocorticoid-Induced Diabetes: Potential Role for Incretin-Based Therapies. S.l.: s.n.; 2013. 275p. Proefschrift VU University, Amsterdam, -. (Promotor(s): Diamant M; copromotor(s): van Raalte DH)
  • van Genugten RE, Möller-Goede DL, van Raalte DH, Diamant M, Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. DIABETES OBES METAB 2013;15 (7):593-606 [PubMed]
  • van Genugten RE, Serné EH, Heymans MW, van Raalte DH, Diamant M, Postprandial microvascular function deteriorates in parallel with gradual worsening of insulin sensitivity and glucose tolerance in men with the metabolic syndrome or type 2 diabetes. DIABETOLOGIA 2013;56 (3):583-587 [PubMed]
  • van Raalte DH, Diamant M, Ouwens DM, Ijzerman RG, Linssen MML, Guigas B, Eringa EC, Serné EH, Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure: a randomised controlled trial. DIABETOLOGIA 2013;56 (11):2383-2391 [PubMed]
  • van Raalte DH, Kwa KAA, van Genugten RE, Tushuizen ME, Holst JJ, Deacon CF, Karemaker JM, Heine RJ, Mari A, Diamant M, Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance?. METABOLISM 2013;62 (4):568-577 [PubMed]

2012

  • den Uyl D, van Raalte DH, Nurmohamed MT, Lems WF, Bijlsma JWJ, Hoes JN, Dijkmans BAC, Diamant M, Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. ARTHRITIS RHEUM-US 2012;64 (3):639-646 [PubMed]
  • van Genugten RE, van Raalte DH, Diamant M, Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. DIABETES OBES METAB 2012;14 (2):101-111 [PubMed]
  • van Raalte D, den Uyl D, Nurmohamed M, Diamant M, Lems W, Hyperglycemia and methylprednisolone: Comment on the article by den Uyl et al Reply. ARTHRITIS RHEUM-US 2012;64 (11):3823
  • van Raalte DH. Diabetogenic Effects of Glucocorticoid Drugs: The Knowns and The Unknowns. S.l.: s.n.; 2012. 337p. ISBN 978-94-6191-423-1 Proefschrift VU University, Amsterdam, -. (Promotor(s): Diamant M; copromotor(s): )
  • van Raalte DH, Brands M, Serlie MJ, Mudde K, Stienstra R, Sauerwein HP, Kersten S, Diamant M, Angiopoietin-Like Protein 4 is Differentially Regulated by Glucocorticoids and Insulin in vitro and in vivo in Healthy Humans. EXP CLIN ENDOCR DIAB 2012;120 (10):598-603 [PubMed]
  • van Raalte DH, van Leeuwen N, Simonis-Bik AM, Nijpels G, van Haeften TW, Schafer SA, Boomsma DI, Kramer MHH, J Heine R, Maassen JA, Staiger H, Machicao F, Häring HU, Slagboom PE, Willemsen G, de Geus EJ, Dekker JM, Fritsche A, Eekhoff EM, Diamant M, 't Hart LM, Glucocorticoid receptor gene polymorphisms are associated with reduced first-phase glucose-stimulated insulin secretion and disposition index in women, but not in men. DIABETIC MED 2012;29 (8):e211-e216 [PubMed]

2011

  • Hoes JN, van der Goes MC, van Raalte DH, van der Zijl NJ, den Uyl D, Lems WF, Lafeber FPGJ, Jacobs JWG, Welsing PMJ, Diamant M, Bijlsma JWJ, Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. ANN RHEUM DIS 2011;70 (11):1887-1894 [PubMed]
  • Linssen MML, van Raalte DH, Toonen EJM, Alkema W, van der Zon GC, Dokter WH, Diamant M, Guigas B, Ouwens DM, Prednisolone-induced beta cell dysfunction is associated with impaired endoplasmic reticulum homeostasis in INS-1E cells. CELL SIGNAL 2011;23 (11):1708-1715 [PubMed]
  • van der Zijl NJ, Goossens GH, Moors CCM, van Raalte DH, Muskiet MHA, Pouwels PJW, Blaak EE, Diamant M, Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on β-cell function in individuals with impaired glucose metabolism. J CLIN ENDOCR METAB 2011;96 (2):459-467 [PubMed]
  • van Raalte DH, Brands M, van der Zijl NJ, Muskiet MH, Pouwels PJW, Ackermans MT, Sauerwein HP, Serlie MJ, Diamant M, Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. DIABETOLOGIA 2011;54 (8):2103-2112 [PubMed]
  • van Raalte DH, Diamant M, Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?. DIABETES RES CLIN PR 2011;93 (Suppl. 1):S37-S46 [PubMed]
  • van Raalte DH, van Genugten RE, Linssen MML, Ouwens DM, Diamant M, Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. DIABETES CARE 2011;34 (2):412-417 [PubMed]

2010

  • van Raalte DH, Nofrate V, Bunck MC, van Iersel T, Elassaiss Schaap J, Nässander UK, Heine RJ, Mari A, Dokter WHA, Diamant M, Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men. EUR J ENDOCRINOL 2010;162 (4):729-735 [PubMed]
  • van Raalte DH, van der Zijl NJ, Diamant M, Pancreatic steatosis in humans: cause or marker of lipotoxicity?. CURR OPIN CLIN NUTR 2010;13 (4):478-485 [PubMed]

2009

  • van Genugten RE, van Raalte DH, Diamant M, Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. DIABETES RES CLIN PR 2009;86 (Suppl. 1):S26-S34 [PubMed]
  • van Raalte DH, Ouwens DM, Diamant M, Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?. EUR J CLIN INVEST 2009;39 (2):81-93 [PubMed]

2005

  • Nierman MC, Rip J, Kuivenhoven JA, van Raalte DH, Hutten BA, Sakai N, Kastelein JJP, Stroes ESG, Carriers of the frequent lipoprotein lipase S447X variant exhibit enhanced postprandial apoprotein B-48 clearance. METABOLISM 2005;54 (11):1499-1503 [PubMed]
  • Rip J, Nierman MC, Sierts JA, Petersen W, van den Oever K, van Raalte D, Ross CJD, Hayden MR, Bakker AC, Dijkhuizen P, Hermens WT, Twisk J, Stroes E, Kastelein JJP, Kuivenhoven JA, Meulenberg JM, Gene therapy for lipoprotein lipase deficiency: Working toward clinical application. HUM GENE THER 2005;16 (11):1276-1286 [PubMed]

2004

  • van Raalte DH, Li M, Pritchard PH, Wasan KM, Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. PHARM RES 2004;21 (9):1531-1538 [PubMed]